Table 3 Classification of patients grouped by NLR < 2.27 (low-NLR-Group) and NLR ≥2.27 (high-NLR-Group)
Low-NLR-Group (n = 47) | High-NLR-Group (n = 32) | P-value | |
|---|---|---|---|
Age (years) | |||
< 61 | 28 (60%) | 10 (31%) | 0.021* |
≥ 61 | 19 (40%) | 22 (69%) | |
Gender (male) | 26 (55%) | 21 (66%) | 0.48 |
Myasthenia gravis | 8 (17%) | 7 (22%) | 0.77 |
WBC (× 109/L) | 7.0 | 8.1 | 0.09 |
Neoadjuvant therapy | 2 (4%) | 1 (3%) | 0.79 |
Adjuvant radiotherapy | 29 (62%) | 18 (56%) | 0.65 |
WHO classification | |||
A | 3 (6%) | 2 (6%) | 0.39 |
AB | 15 (32%) | 17 (53%) | |
B1 | 12 (26%) | 4 (13%) | |
B2 | 7 (15%) | 4 (13%) | |
B3 | 10 (21%) | 5 (15%) | |
Masaoka-Koga stage | |||
I | 12 (26%) | 9 (28%) | 0.68 |
II | 23 (49%) | 18 (56%) | |
III | 11 (23%) | 5 (16%) | |
IV | 1 (2%) | 0 (0%) | |
TNM stage | |||
I | 37 (79%) | 28 (88%) | 0.028* |
II | 0 (0%) | 2 (6%) | |
IIIA | 10 (21%) | 1 (3%) | |
IIIB | 0 (0%) | 1 (3%) | |